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Abstract
Background: Constitutional mismatch repair deficiency syndrome results from bi-allelic inheritance of mutations
affecting the key DNA mismatch repair genes: MLH1, MSH2, MSH6 or PMS2. Individuals with bi-allelic mutations have
a dysfunctional mismatch repair system from birth; as a result, constitutional mismatch repair deficiency syndrome
is characterised by early onset malignancies. Fewer than 150 cases have been reported in the literature over the
past 20 years. This is the first report of the founder PMS2 mutation - NM_000535.5:c.1500del (p.Val501TrpfsTer94) in
exon 11 and its associated cancers in this family.
Case presentation: The proband is 30 years old and is alive today. She is of Pakistani ethnic origin and a product
of consanguinity. She initially presented aged 24 with painless bleeding per-rectum from colorectal polyps and was
referred to clinical genetics. Clinical examination revealed two café-au-lait lesions, lichen planus, and a dermoid cyst.
Her sister had been diagnosed in childhood with an aggressive brain tumour followed by colorectal cancer. During
follow up, the proband developed 37 colorectal adenomatous polyps, synchronous ovarian and endometrial
adenocarcinomas, and ultimately a metachronous gastric adenocarcinoma. DNA sequencing of peripheral
lymphocytes revealed a bi-allelic inheritance of the PMS2 mutation NM_000535.5:c.1500del (p.Val501TrpfsTer94) in
exon 11. Ovarian tumour tissue demonstrated low microsatellite instability. To date, she has had a total abdominal
hysterectomy, bilateral salpingo-oophorectomy, and a total gastrectomy. Aspirin and oestrogen-only hormone
replacement therapy provide some chemoprophylaxis and manage postmenopausal symptoms, respectively. An
18-monthly colonoscopy surveillance programme has led to the excision of three high-grade dysplastic colorectal
tubular adenomatous polyps. The proband’s family pedigree displays multiple relatives with cancers including a
likely case of ‘true’ Turcot syndrome.
Conclusions: Constitutional mismatch repair deficiency syndrome should be considered in patients who present
with early onset cancer, a strong family history of cancer, and cutaneous features resembling neurofibromatosis
type I. Immunohistochemistry analysis of tumour and normal tissue is sensitive and specific for identifying patients
with mismatch repair deficiency and should direct DNA sequencing of lymphocytic tissue to establish a diagnosis.
Microsatellite instability status appears to be of little value in identifying patients who may have constitutional
mismatch repair deficiency syndrome.
Keywords: Constitutional mismatch repair deficiency, CMMRD, Mismatch repair, MMR, PMS2, Lynch syndrome,
Turcot syndrome
* Correspondence: neilryan@nhs.net
2Clinical Research Fellow, Division of Molecular & Clinical Cancer Sciences,
Faculty of Biology, Medicine and Health, Fifth Floor - Research, St Mary’s
Hospital, University of Manchester, Oxford Road, Manchester M13 9WL, UK
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ramchander et al. BMC Medical Genetics  (2017) 18:40 
DOI 10.1186/s12881-017-0391-x
Background
Mismatch repair (MMR) proteins maintain genomic
stability [1]. Four of these proteins are pivotal to DNA
mismatch repair: MLH1, MSH2, MSH6 and PMS2.
Mismatch repair involves the recognition and correction
of single DNA base-base mismatches and insertion-
deletion loops (IDL’s) that arise during cellular replica-
tion, preventing these mutations from persisting in
daughter cells [2].
Lynch syndrome (formerly known as hereditary non-
polyposis colorectal cancer or HNPCC) is an autosomal
dominant cancer predisposition syndrome with a vari-
able penetrance; it results from the inheritance of a het-
erozygous mutation affecting one of the key mismatch
repair genes: MLH1, MSH2, MSH6, or PMS2 [3–5].
The loss of the wild-type allele leads to MMR deficiency,
and a hyper-mutated phenotype. The repetitive coding se-
quences of microsatellites are particularly susceptible to
acquiring insertions and deletions of nucleotide bases
during cellular replication, which result in frameshift
mutations. Mismatch repair deficiency promotes the per-
sistence of these frameshift mutations in daughter cells,
measured as microsatellite instability (MSI). Microsatellite
instability-high (MSI-H) tumours are characteristic of
Lynch syndrome associated colorectal cancer (CRC) [6]. A
severe variant of Lynch syndrome is constitutional
mismatch repair deficiency (CMMRD), which results from
bi-allelic inheritance of an MMR gene mutation [7, 8].
With it comes a poor prognosis; over 50% of patients
develop malignant brain tumours, over 30% develop
haematological malignancies, and 40% develop digestive
tract tumours, all at very young ages [9]. The most fre-
quent cancers observed in CMMRD are brain gliomas,
non-Hodgkin’s lymphomas and CRC’s, with an average
age at diagnosis of 9.5 years, 5 years, and 16 years, respect-
ively [10]. The cancer spectrum in CMMRD appears to be
related to the gene mutated; homozygous carriers of
MSH6 and PMS2 mutations develop brain tumours in the
first decade of life [10]. Importantly, over 40% of individ-
uals homozygous for a PMS2 mutation develop second
primary malignancies. This is in contrast to the 22% of in-
dividuals homozygous for MLH1/MSH2 mutations that
develop second primary malignancies [10]. This difference
may be because individuals with homozygous PMS2 mu-
tations often survive their first malignancy, unlike their
MLH1/MSH2 counterparts who develop aggressive haem-
atological malignancies at an average age of 2.5 years.
Café-au-lait (CAL) lesions are the most common derma-
tological manifestation of individuals with CMMRD [11].
Consanguinity of the parents and/or homozygosity for a
founder mutation is observed in over 50% of reported
cases of CMMRD.
Case presentation
The proband is a 30-year-old female of Pakistani ethnic
origin and a product of consanguinity; her parents are dis-
tant cousins. Her family pedigree is depicted in Fig. 1. The
prominent feature was that a sister (III:1) had developed a
high-grade parietal lobe astrocytoma aged 10 years but
died from a metastatic primary adenocarcinoma of the
Fig. 1 Family pedigree for the familial PMS2 mutation NM_000535.5:c.1500del (p.Val501TrpfsTer94) in exon 11, of a family of Pakistani ethnic
origin living in the UK. The proband (III:3, arrow), is homozygous for this PMS2 mutation. She presented with café-au-lait lesions, lichen planus, a
dermoid cyst, and bleeding per-rectum. She has developed 37 benign colorectal adenomatous polyps to date. She has developed ovarian and
endometrial cancer (both at age 26) and gastric cancer (age 28). III:1 developed a parietal lobe astrocytoma (age 10) and a caecal adenocarcinoma
of which she died (age 20); her mutation status is unknown, however III:1’s history is representative of true Turcot syndrome. III:9 died of a brain
tumour (age 17); her mutation status is unknown. III:5 has declined genetic testing for the time being. II:5 and II:6, II:7 and II:8, II:11 and II:12 are
distant cousins
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caecum aged 20 years. The proband (III:3) presented aged
24 years, with painless bleeding per-rectum (PR) and iron
deficiency anaemia. This was investigated by colonoscopy
at which 10 colonic tubullo-villous adenomatous polyps
with low-grade dysplasia were excised. Further clinical in-
vestigation was prompted by her unusual presentation.
On examination, she had two distinct CAL lesions, one
on her right arm and one on her left leg. Both CAL lesions
had irregular edges with foci of hypopigmentation within
areas of hyperpigmentation (Fig. 2). She also had wide-
spread lichen planus mostly concentrated to her lower
limbs, and a dermoid cyst on her left lower back.
Initial investigations were for MUTYH associated
polyposis (MAP) and Lynch syndrome given the early
age of onset of polyps, dermatological manifestations,
and very early onset family history of CRC. Direct se-
quencing of lymphocytic tissue for MUTYH did not re-
veal any mutations. All tissue analyses performed are
summarised in Table 1. Initial immunohistochemistry
(IHC) analysis was deemed inconclusive for Lynch syn-
drome due to perceived poor technical quality of PMS2
staining; there was universal absence of PMS2 antibody
uptake in tumour and control tissue.
A pelvic ultrasound scan was performed later that year
when the patient reported symptoms of bloating. This re-
vealed malignant-looking bilateral ovarian cysts. Bilateral
ovarian cystectomy revealed grade 1/grade 2 endometrioid
adenocarcinomas affecting both ovaries. Peritoneal wash-
ings demonstrated the presence of adenocarcinoma cells.
The proband’s tumour phenotype is summarised in Table 2.
Immunohistochemistry was repeated on ovarian tissue; 0%
tumour positivity and 0% control positivity for PMS2 was
established. Microsatellite instability analysis demonstrated
the ovarian tumour to be microsatellite instability-low
(MSI-L). Sanger dye terminator sequencing of lymphocytic
tissue identified that the proband was homozygous for the
PMS2 founder mutation NM_000535.5:c.1500del (p.Val501
TrpfsTer94) in exon 11, and a diagnosis of CMMRD was
made (Fig. 3). The described PMS2 mutation NM_00
0535.5:c.1500del (p.Val501TrpfsTer94) leads to a down-
stream stop codon at the 94th amino acid, creating a trun-
cated protein. Given the lack of protein expression on
IHC, it is likely that truncation leads to nonsense mediated
decay with no protein product. The variant has been seen
twice on the Exome Aggregation Consortium (ExAc) with
Fig. 2 Photograph of the proband’s left leg showing café-au-lait
lesions on a background of lichen planus
Table 1 Molecular analysis of polypoid and cancerous tumour
tissue resected from the proband
Mismatch repair protein immunohistochemistry
Colorectal polypoid
tissue
• >80% positivity for MLH1, MSH2 and MSH6
• Inconclusive result for PMS2 (reported poor
technical quality of staining)
Ovarian tumour
tissue
• >80% positivity for MLH1, MSH2, MSH6
• 0% positivity for PMS2. In addition, there was









• Positive for CK7, CDX2 with focal positivity
for CX20
• Negative expression of ER, PR, WT1,
PAX8 and GCDFP15
• There was no evidence of loss of
E-cadherin expression
Molecular characteristics of the colorectal polypoid tissue, ovarian cancer
tumour tissue, and gastric cancer tumour tissue resected from the proband.
Initial colorectal polypoid tissue analysis was deemed inconclusive due to
perceived poor technical quality of the staining due to universally absent
uptake of the PMS2 antibody
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a frequency of 0.0000165, which represents 2 of 30,610
individuals tested.
The proband underwent full staging surgery with a
total abdominal hysterectomy (TAH), bilateral salpingo-
oophorectomy (BSO), and partial omentectomy. No
residual ovarian disease was present, which corresponds
to an International Federation of Gynecology and Ob-
stetrics FIGO Stage 1c (Grade 2) endometrioid adeno-
carcinoma of the ovary. An incidental, synchronous
FIGO Stage 1a (Grade 1) endometrioid adenocarcinoma
of the endometrium was identified during routine post
operative histological examination of the uterus. Adju-
vant chemotherapy was not used.
The proband was then initiated on an 18-monthly
colonoscopy-surveillance program and advised to take
daily aspirin (75mg-150mg) for chemoprevention against
MSI-H CRC. In total, the proband has had 37 adenoma-
tous large bowel polyps excised; three of these were
high-grade dysplastic tubular adenomatous polyps of the
rectosigmoid that were identified and excised as part of
her surveillance programme following diagnosis. She
was also initiated on oestrogen-only hormone replace-
ment therapy (HRT) following unsuccessful vasomotor
menopausal treatment with venlafaxine.
The following year she developed nausea and vomiting,
and as a result, an urgent oesophago-gastro-duodenoscopy
was performed. Gastric biopsy revealed a poorly differenti-
ated adenocarcinoma in the body of the stomach and con-
firmed it was a primary tumour that did not represent
recurrence (Table 1). She was treated with neoadjuvant
chemotherapy followed by total gastrectomy and comple-
tion of omentectomy, with the excision of 0.5 cm of the
lower oesophagus and 1.3 cm of the duodenum. This
revealed a poorly differentiated primary gastric adeno-
carcinoma (T3N2M0) with diffuse widespread infiltra-
tion through the muscularis propria into the subserosal
tissue. Four lymph nodes showed evidence of meta-
static adenocarcinoma.
Table 2 Cancer tumour tissue histology and the management of malignancies in the proband
Year Proband’s age Location Tumour histology Stage (Grade) Management
Aug. 2012 26y9m Ovaries Endometrioid adenocarcinoma FIGO Stage 1c (Grade 2) Total abdominal hysterectomy with
bilateral salpingo-oophorectomy
Oct. 2012 26y10m Uterus Endometrioid adenocarcinoma FIGO 2009 Stage 1a (Grade 1) Total abdominal hysterectomy with
bilateral salpingo-oophorectomy
Dec. 2013 28y0m Stomach Gastric Adenocarcinoma T3N2M0 (Grade 3) Total gastrectomy with neoadjuvant
chemotherapy
The proband has developed multiple malignancies since first presenting at age 24. Her first malignancy (ovarian cancer) was diagnosed less than three years after
initial presentation. Despite presenting with bleeding PR, the patient has not yet developed colorectal cancer. Aggressive surgical management was used for her
gynaecological malignancies, and a combination of neoadjuvant chemotherapy and surgery was used for her gastric malignancy
Fig. 3 Sanger sequence of the proband’s peripheral lymphocytes showing PMS2 mutation NM_000535.5:c.1500del (p.Val501TrpfsTer94) in exon
11. Arrow points to homozygous loss of cytosine at the 1500 frame
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Immunohistochemistry analysis for MLH1, MSH2,
MSH6 and PMS2 was performed on 4μm formalin fixed,
paraffin embedded tissue sections using the automated
Ventana BenchMark ULTRA IHC/ISH Staining Module
(Ventana Co., Tucson, AZ, United States) together with
the OptiView, 3′ diaminobenzidine (DAB) version 5
detection system (Ventana Co., Tucson, AZ, United
States). 0% staining intensity for an MMR protein was
regarded as negative expression of that protein.
Microsatellite instability analysis was performed on
ovarian tumour tissue using the Promega MSI analysis
system v1.2 (Wisconsin, United States). The MSI Ana-
lysis System includes fluorescently labelled primers for
co-amplification of seven markers including five mono-
nucleotide repeat markers (BAT-25, BAT-26, NR-21,
NR-24 and MONO-27) and two pentanucleotide repeat
markers (Penta C and Penta D). The mononucleotide
markers were used for MSI determination, and the pen-
tanucleotide markers were used to detect potential sam-
ple mix-ups and/or contamination. In addition, control
lymphocytic tissue from the proband was analysed using
the same platform.
Peripheral lymphocytes were utilised for genetic se-
quencing. Mutations in the MUTYH (formerly known as
MYH) and MMR genes were searched for using dye ter-
minator Sanger sequencing on ABI Genetic Analysis of
the exon regions of the coding sequences. Sequence
analysis of exons 2, 4, 6, 7, 13 and 14 of the MUTYH
gene was used to detect common Indian and Pakistani
mutations (p.Tyr104Ter and p.Glu480Ter) and common
European mutations (p.Tyr179Cys and p.Glu396Asp).
The reference sequence for the MUTYH gene was
NM_001128425.1. All 19 exons in MLH1, 16 exons in
MSH2 and 10 exons in MSH6 were sequenced in both
directions. Analysis of mutations in the PMS2 exon
coding sequence was complicated by presence of mul-
tiple pseudogenes corresponding to exons 1–5 of PMS2
and a single large pseudogene encompassing exons 9
and 11–15 of PMS2. Exon 11 particularly had a high
homology to the pseudogene. Long range PCR was per-
formed first to amplify PMS2 (and not the pseudogene
PMS2CL) prior to Sanger sequencing. Multiple ligation
dependent probe amplification (MLPA) was used to de-
tect dosage abnormalities in exons 1–11 of PMS2 using
kit P008-B1 [MRC-Holland]. Due to gene conversion
and technical issues, analysis of exons 13–15 was not
performed. The reference sequence for PMS2 was
NM_000535.5.
Tissue analysis results are summarised in Table 1. Of
note, the initial IHC staining of polypoid tissue and non-
malignant control tissue was deemed inconclusive due
to absent uptake of the PMS2 antibody in both the
polypoid tissue and control tissue; this was attributed to
poor technical quality of the staining. This delayed
diagnosis until subsequent IHC analysis of the ovarian
tumour, which established 0% immunopositivity for PMS2
in tumour tissue and control tissue. This prompted DNA
sequencing of lymphocytic tissue, resulting in diagnosis of




Here we present the rare case of a young woman with
CMMRD, a severe variant of Lynch syndrome. The pro-
band presented in her twenties with PR bleeding, went
on to develop multiple gynaecological malignancies, and
ultimately, an advanced primary gastric tumour. Both of
these cancer types are rare amongst individuals with
CMMRD; the later represents the first reported gastric
malignancy in a confirmed case of CMMRD. CMMRD is
rare and poses both a diagnostic and managerial chal-
lenge. It is interesting to note the delay in onset of dis-
ease in this individual. One may speculate that this
results from retained PMS2 function despite the muta-
tion. The complete loss of protein expression on IHC
suggests that this explanation is unlikely. In addition,
pathological mutations identified in distal exons indicate
the structural functionality of PMS2 lies beyond exon
11. Both of these observations would support nonsense
decay of PMS2 consequent to the reported mutation.
A review of 146 cases of CMMRD conducted by
Wimmer et al. concluded that PMS2 mutations were re-
sponsible for 60% of cases, with the remaining being
MLH1, MSH2 and MSH6 mutations; this is in contrast
to Lynch syndrome, where heterozygous MLH1 and
MSH2 mutations are responsible for the majority of
cases [10]. In CMMRD, MLH1/MSH2 mutations carry a
worse prognosis compared to MSH6/PMS2 mutations;
individuals with MSH6 or PMS2 mutations often survive
their first malignancy and develop secondary malignan-
cies, as was the case in the proband. Heterozygous
PMS2 mutations appear to display an attenuated Lynch
syndrome phenotype. This is reflected not only by the
later age of onset of cancer, but also by the lower pene-
trance of cancer [12]. A potential explanation for this
could be the partial compensation of absent PMS2 by
MLH3, which can form a functional heterodimeric pro-
tein with MLH1 that has mismatch repair capacity [5].
Neither of the proband’s parents have a history of can-
cer, reflecting this attenuated phenotype. This presents a
diagnostic challenge and highlights the difficulty in iden-
tifying familial PMS2 mutations. Several features in the
history alluded to a severe inherited cancer predispos-
ition. This included the family history of childhood ma-
lignancies, parental consanguinity, early presentation of
the patient and the presence of cutaneous signs resem-
bling neurofibromatosis type I (NF-1). The identification
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of the proband’s homozygous PMS2 mutation status has
led to the diagnosis of several family members with
Lynch syndrome (Fig. 1).
Bakry et al. report that immunohistochemistry of
tumour tissue and intratumoural normal tissue is 100%
sensitive in detecting MMR deficiency resulting from bi-
allelic gene inactivation in CMMRD [8]. Therefore, in
cases of early onset cancer, with a history of consanguin-
ity and cutaneous features resembling NF-1, Durno et al.
propose performing IHC for MMR proteins on tumour
and normal tissue; abnormal IHC in both tumour and
normal tissue should alert to CMMRD, and relevant
DNA sequencing should follow [11]. Microsatellite in-
stability is the molecular hallmark of Lynch syndrome
associated tumours, and hence MSI status is part of the
revised Bethesda guidelines for identifying Lynch syn-
drome [6, 13]. Microsatellite instability status in CMMRD,
however, has been reported as neither sensitive nor spe-
cific; particularly in extra-intestinal tumours [8]. This sug-
gests it is less reliable as an assessment tool for CMMRD
than it is for Lynch syndrome. In the proband, therefore,
the fact that her ovarian tumour was MSI-L did not
prevent escalation of investigation for MMR deficiency to
include genetic sequencing.
Another diagnostic challenge arises from the presenta-
tion individuals with CMMRD: often with CAL lesions,
which raises the differential of NF-1. Neurofibromatosis
type I is an autosomal dominant condition, and a clinical
diagnosis can be made using the National Institute of
Health (NIH) criteria [14]. Whilst other features of NF-1
are observed in patients with CMMRD, such as Lisch
nodules, plexiform neurofibromas and axillary freckling,
they rarely meet the diagnostic criteria [15]. The pro-
band did not meet these criteria. The CAL lesions ob-
served in the proband displayed diffuse borders with
areas of hypopigmentation within lesions of hyperpig-
mentation, as reported elsewhere in the CMMRD litera-
ture [10]. This is in contrast to the homogenous, well-
demarcated CAL lesions observed in NF-1 [14, 16, 17].
Looking to other reported cases of CMMRD, brain tu-
mours have been observed in 53% of cases [9]. Gliomas
are the most common, and present in the first decade of
life. Other brain tumours include supratentorial neu-
roectodermal tumours and meduloblastomas. III:1 devel-
oped a parietal lobe astrocytoma aged 10 followed by
CRC aged 20. Genetic testing was never performed,
however her history strongly reflects PMS2 mutation
homozygosity. It is interesting to note that III:1’s history
could be representative of ‘true’ Turcot syndrome. Brain
tumour polyposis syndrome (BTPS) is defined by a com-
bination of synchronous or metasynchronous brain and
colonic neoplasms [18–20]. BTPS is divided into type 1
and type 2. The distinctions between BTPS type 1 and
BTPS type 2 lie in their modes of inheritance and
tumour phenotypes. BTPS type 1 refers to autosomal
recessive inheritance of MMR gene mutations with the
development of Lynch syndrome and the childhood (<20
years) onset of brain glial tumours (glioblastomas or as-
trocytomas). BTPS type 1 is in keeping with McKusick’s
original description of Turcot syndrome and with a
CMMRD spectrum disease [21, 22]. BTPS type 2 refers
to autosomal dominant inheritance of APC gene muta-
tions with the development of Familial Adenomatous
Polyposis (FAP), and the development of brain medullo-
blastomas [20]. The authors suggest that a diagnosis of
Turcot syndrome be restricted to patients with homozy-
gous loss of MMR, that is CMMRD, and not in those
with heterozygous loss of MMR or FAP with neuro-
logical tumours.
The management of CMMRD individuals is without a
solid evidence base. The effectiveness of chemotherapy
in patients with MSI-H Lynch syndrome associated
tumours is unknown; there is some evidence that these
tumours are less responsive to 5-fluorouracil based
chemotherapy [23, 24]. Importantly, there is also the
possibility of accelerated mutagenesis and the develop-
ment of second malignancies when CMMRD cells are
exposed to alkylating agents [25]. Our patient was not
treated with adjuvant chemotherapy. This was in light of
the uncertain benefit of such treatment in CMMRD and
the risk of accelerated tumourigenesis. The patient did
however receive neoadjuvant chemotherapy preceding
her gastrectomy.
Another important aspect of the proband’s manage-
ment was the decision to start her on oestrogen-only
HRT. This was to reduce the symptoms of menopause,
as well as protect against the development of CRC and
osteoporosis. The proband was also advised to take daily
aspirin. This has been shown to reduce the incidence of
CRC in Lynch syndrome [26]. Further clarity is required
regarding its efficacy in CMMRD patients, as the mo-
lecular mechanism of aspirin in preventing colorectal
cancer is attributed to its suppressive effect of an MSI
phenotype, via a nitric oxide mediated genetic selection
that enhanced apoptosis of cells undergoing MSI [27].
A wide tumour phenotype is observed in CMMRD as
well as a variable age of tumour onset. The age-dependent
levels of mitotic activity in local tissue could explain this.
Tissue with increased mitotic activity, combined with an
inability to correct accumulating DNA mismatches and
IDL’s, is predisposed to tumourigenesis. This wide tumour
spectrum complicates the implementation of an effective,
comprehensive surveillance program. Screening should
target the most common cancers observed in CMMRD
patients for that age group. The European Consortium
provided screening guidance for the management of indi-
viduals with CMMRD [9]. The routine colonoscopy sur-
veillance of patients with Lynch syndrome has reduced
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CRC-mortality by over 60% [28]. To improve sensitivity, it
is recommended to combine chromoscopy with colonos-
copy [29, 30]. The European Consortium recommend
annual video-capsule endoscopy (VCE) and ileocolono-
scopy for patients with CMMRD to identify small and
large bowel cancer [9]. Patients with CMMRD who have
multiple colorectal adenomas are recommended a shorter
screening interval of 6 months. The proband is currently
on an 18-monthly colonoscopy and VCE-screening pro-
gram, in keeping with the standard UK Lynch syndrome
protocol [31]. An annual or 6-monthly colonoscopy pro-
gram was not utilised due to the absence of a robust evi-
dence base and the difficulty of the bowel prep following
her gastrectomy. Her surveillance program has resulted in
the identification and excision of three adenomatous
polyps with high-grade dysplasia, and so in the proband,
surveillance has been successful.
Psychosocial support is central to providing holistic
care for patients, as well as the families of patients, with
CMMRD. This can improve familial uptake of diagnostic
testing and compliance with surveillance programs [32].
The use of a multidisciplinary team throughout the
proband and her family’s care has therefore been, and
continues to be, vital.
Conclusions
In conclusion, the proband is part of the novel CMMRD
cohort described over the last 20 years; we describe here
for the first time her family’s PMS2 mutation. She is
unique within this cohort in that she did not develop a
childhood malignancy, but rather presented in the third
decade of her life with rectal bleeding. Even more interest-
ing is that further investigation did not reveal cancer. Her
primary tumours were bilateral ovarian endometrioid
adenocarcinomas. Her gastric malignancy was a meta-
chronous tumour unrelated to her endometrial and
ovarian tumours and represents the first of its kind in
the CMMRD literature. Constitutional mismatch re-
pair deficiency is a poorly described cancer predispos-
ition syndrome. We have outlined the diagnosis and
treatment of this case, which highlights the complex-
ity of diagnosing CMMRD. The proposed guidelines
by Durno et al. for identifying patients at risk of
having CMMRD, along with the European consortium’s
proposed guidelines on surveillance in CMMRD, are
therefore invaluable resources and should be used to
direct the diagnosis and management of individuals
with CMMRD [9, 11].
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